TY  - JOUR
A1  - Krzymanski, M.
A1  - Waaga, A. M.
A1  - Ulrichs, Karin
A1  - Müller-Ruchholtz, Wolfgang
T1  - Long-standing rat kidney graft survival by a combination of organ perfusion with MHC class II monoclonal antibody and immunosuppression with reduced doses of 15-deoxyspergualin.
N2  - No abstract available
KW  - Niere
KW  - Ratte
KW  - MHC Klasse II
KW  - kidney
KW  - rat
Y1  - 1991
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-64442
ER  - 
TY  - JOUR
A1  - Krzymanski, Maciej
A1  - Waaga, Ana M.
A1  - Ulrichs, Karin
A1  - Deja, Aadam
A1  - Oko, Andrzej
A1  - Rommel, Thomas
A1  - Müller-Ruchholtz, Wolfgang
T1  - The influence of MHC class II antigen blockade by perfusion with a monoclonal antibody on rat renal graft survival
N2  - To decrease immunogenicity of the rat kidney, grafts were perfused with an anti-MHC class li monoclonal antibody (mAb ). How effectively this procedure blocked dass li-positive cells, which were mainly dendritic in appearance, was checked by immunostaining renal sections after perfusion and comparing them with in vitro stained sections. Optimum conditions were applied for graft pretreatment before transplantation. This procedure prolonged graft survival, though not satisfactorily from the biological point ofview (9.6 ± 0.8 versus 7.7 ± 0.5 days in the control group; P < 0.02). The dendritic cells were not killed but blocked. Several hours after transplantation, the mAb dissociated from these dass li-positive cells. It was also shown that donor cells migrate into the recipient's spieen early after transplantation. The number of these cells was smaller when the transplanted organ was perfused with the mAb. Further studies are suggested to deplete the graft of donor dendritic cells more adequately. They should also combine graft perfusion with antidass II mAb and recipient immunosuppression at reduced doses.
KW  - Chirurgie
KW  - Class II antigen blockade
KW  - rat
KW  - renal transplantation
KW  - Monoclonal antibody
KW  - dass II antigen blockade
Y1  - 1991
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-64431
ER  - 
TY  - JOUR
A1  - Waaga, AM
A1  - Ulrichs, Karin
A1  - Krzymanski, M.
A1  - Treumer, J.
A1  - Hansmann, ML
A1  - Rommel, T.
A1  - Müller-Ruchholz, W.
T1  - The immunosuppressive agent 15-deoxyspergualin induces tolerance and modulates MHC-antigen expression and interleukin-1 production in the early phase of rat allograft responses
N2  - No abstract available
KW  - Chirurgie
Y1  - 1990
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-45253
ER  - 
TY  - JOUR
A1  - Waaga, AM
A1  - Krzymanski, M.
A1  - Ulrichs, Karin
A1  - Wierusz-Wysocka, Bogna
A1  - Müller-Buchholtz, Wolfgang
T1  - Hematological effects of the new immunosuppressive drug 15-deoxyspergualin
N2  - Since systematic hematological studies on blood and bone marrow changes after treatment with 15-Deoxyspergualin (DOS) are lacking, a quantitative assessment was performed fourteen or twenty eight days after intraperitoneal application of DOS to rats. Further observations done 7 and 14 days after discontinuation of DOS administration allowed analysis of banc marrow regeneration. DOS induced lymphocytopenia, granUlocytopenia and anemia with a decrease of bone marrow cellularity due to suppression of cell maturation. The effect was dose-dependent and bone marrow as well as blood changes were observed in animals treated with doses from 0.5 to 10.0 mg/kg DOS. Within 14 days after termination of the treatment, rapid recovery with normalization of all hematological parameters was observed. In the light of our data, these hematological side effects may not be a major disadvantage, if DOS is used in doses below 2.5 mg/kg, and for a course of therapy which is limited to 7 to 14 days.
KW  - Chirurgie
KW  - 15-Deoxyspergualin
KW  - hematology
KW  - immunosuppression
KW  - bone marrow
KW  - regeneration
KW  - experimental therapy
Y1  - 1993
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-44701
ER  -